1. Academic Validation
  2. Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core

Discovery of a Potent, Injectable Inhibitor of Aurora Kinases Based on the Imidazo-[1,2-a]-Pyrazine Core

  • ACS Med Chem Lett. 2010 Jun 7;1(5):214-8. doi: 10.1021/ml100063w.
Tao Yu 1 Jayaram R Tagat 1 Angela D Kerekes 1 Ronald J Doll 1 Yonglian Zhang 1 Yushi Xiao 1 Sara Esposite 1 David B Belanger 2 Patrick J Curran 2 Amit K Mandal 2 M Arshad Siddiqui 2 Neng-Yang Shih 2 Andrea D Basso 3 Ming Liu 3 Kimberly Gray 3 Seema Tevar 3 Jennifer Jones 3 Suining Lee 3 Lianzhu Liang 3 Samad Ponery 3 Elizabeth B Smith 3 Alan Hruza 4 Johannes Voigt 4 Lata Ramanathan 4 Winifred Prosise 4 Mengwei Hu 5
Affiliations

Affiliations

  • 1 Departments of Chemical Research.
  • 2 Department of Chemical Research.
  • 3 Oncology.
  • 4 Structural Chemistry.
  • 5 Pharmaceutical Sciences.
Abstract

The imidazo-[1,2-a]-pyrazine (1) is a dual inhibitor of Aurora kinases A and B with modest cell potency (IC50 = 250 nM) and low solubility (5 μM). Lead optimization guided by the binding mode led to the acyclic amino alcohol 12k (SCH 1473759), which is a picomolar inhibitor of Aurora kinases (TdF K d Aur A = 0.02 nM and Aur B = 0.03 nM) with improved cell potency (phos-HH3 inhibition IC50 = 25 nM) and intrinsic aqueous solubility (11.4 mM). It also demonstrated efficacy and target engagement in human tumor xenograft mouse models.

Keywords

Aurora kinase inhibitors; SCH 1473759; aqueous solubility; cell potency; imidazo-[1,2-a]-pyrazine; tumor xenograft model.

Figures
Products